Hydromorphone for cancer pain

Keyphrases

• Hydromorphone 100%
• Cancer Pain 100%
• Randomized Controlled Trial 60%
• Confidence Interval 55%
• Risk Ratio 50%
• Morphine 40%
• Pain Intensity 40%
• Quality of Life 35%
• Adverse Events 35%
• Pain Relief 35%
• Oxycodone 30%
• Fentanyl 25%
• Reporting Quality 15%
• Risk of Bias 15%
• Placebo 15%
• Constipation 15%
• Dizziness 15%
• High Risk 10%
• Visual Analog Scale 10%
• Nausea 10%
• Vomiting 10%
• Analgesic 10%
• Uncertain Risk 10%
• Search Methods 5%
• Extracted Data 5%
• Selection Criteria 5%
• MEDLINE 5%
• Embase 5%
• Opioid Analgesics 5%
• Absence of Evidence 5%
• Active Control 5%
• Meta-analysis 5%
• Disease Progression 5%
• Advanced Cancer 5%
• Between-group 5%
• Random Effects Model 5%
• Serious Adverse Events 5%
• Continuous Data 5%
• Adult Cancer 5%
• Binary Outcome 5%
• Opioids 5%
• Days of Treatment 5%
• Summary of Findings Table 5%
• Cochrane Review 5%
• Clinical Trial Registry 5%
• Review Authors 5%
• Calculated Risk 5%
• Intention-to-treat 5%
• Analgesic Efficacy 5%
• Publication Status 5%
• Document Types 5%
• Type Status 5%
• Distress Symptoms 5%
• Skewed Data 5%
• Pain Prevalence 5%
• Relief Measures 5%
• Opioid Pharmacotherapy 5%
• Large Sample Size 5%
• Numerical Rating Scale 5%
• Brief Pain Inventory 5%
• Event Quality 5%
• Nausea-vomiting 5%

Nursing and Health Professions

• Cancer Pain 100%
• Hydromorphone 100%
• Confidence Interval 55%
• Adverse Event 40%
• Pain Intensity 40%
• Morphine 40%
• Quality of Life 35%
• Analgesia 35%
• Oxycodone 30%
• Duragesic 25%
• Placebo 15%
• Analgesic Agent 15%
• Dizziness 15%
• Constipation 15%
• Nausea 15%
• Symptom 10%
• Opiate 10%
• Visual Analog Scale 10%
• Prevalence 5%
• Disease 5%
• Sample Size 5%
• Drug Therapy 5%
• Meta Analysis 5%
• Embase 5%
• Intention to Treat Analysis 5%
• Narcotic Analgesic Agent 5%
• Advanced Cancer 5%
• Brief Pain Inventory 5%
• Numeric Rating Scale 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Hydromorphone 100%
• Cancer Pain 100%
• Randomized Controlled Trial 60%
• Adverse Event 40%
• Morphine 40%
• Oxycodone 30%
• Duragesic 25%
• Placebo 15%
• Nausea 15%
• Analgesic Agent 15%
• Constipation 15%
• Dizziness 15%
• Symptom 10%
• Opiate 10%
• Prevalence 5%
• Disease 5%
• Clinical Trial 5%
• Narcotic Analgesic Agent 5%
• Pharmacotherapy 5%
• Random Effects Model 5%
• Advanced Cancer 5%